XORTX Therapeutics Files October 2024 6-K Report
Ticker: XRTX · Form: 6-K · Filed: Oct 24, 2024 · CIK: 1729214
Sentiment: neutral
Topics: filing, 6-K, regulatory
TL;DR
XORTX files its monthly 6-K, confirming 20-F annual reports. CEO Davidoff signed off.
AI Summary
XORTX Therapeutics Inc. filed a Form 6-K on October 24, 2024, to report its activities for the month of October 2024. The filing indicates that the company is a foreign private issuer and will file its annual reports under Form 20-F. Allen Davidoff, the Chief Executive Officer, signed the report.
Why It Matters
This filing provides routine updates from XORTX Therapeutics Inc. as a foreign private issuer, confirming their reporting structure and filing status with the SEC.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not contain new financial or operational information that would significantly alter risk.
Key Players & Entities
- XORTX Therapeutics Inc. (company) — Registrant
- Allen Davidoff (person) — Chief Executive Officer
- October 24, 2024 (date) — Filing date
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to provide information that the company may be required to disclose or make public in its home country.
Which form will XORTX Therapeutics Inc. use for its annual reports?
XORTX Therapeutics Inc. will file its annual reports under cover of Form 20-F.
Who signed the Form 6-K filing on behalf of XORTX Therapeutics Inc.?
Allen Davidoff, the Chief Executive Officer of XORTX Therapeutics Inc., signed the Form 6-K filing.
What is the filing date of this Form 6-K?
This Form 6-K was filed on October 24, 2024.
What is the SIC code for XORTX Therapeutics Inc.?
The Standard Industrial Classification (SIC) code for XORTX Therapeutics Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 139 words · 1 min read · ~1 pages · Grade level 10.7 · Accepted 2024-10-24 08:11:28
Filing Documents
- f6k_102424.htm (6-K) — 4KB
- exh_991.htm (EX-99.1) — 9KB
- 0001171843-24-005803.txt ( ) — 14KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-40858 XORTX Therapeutics Inc. 3710 – 33rd Street NW, Calgary, Alberta, T2L 2M1 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ] SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. XORTX Therapeutics Inc. (Registrant) Date: October 24, 2024 By: /s/ Allen Davidoff Name: Allen Davidoff Title: Chief Executive Officer EXHIBIT INDEX 99.1 News release dated October 24, 2024